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Abstract
Background: Antisense oligonucleotide-induced exon skipping is a promising approach for treatment of Duchenne
muscular dystrophy (DMD). We have systemically administered an antisense phosphorodiamidate morpholino oligomer
(PMO) targeting dystrophin exons 6 and 8 to a dog with canine X-linked muscular dystrophy in Japan (CXMDJ) lacking exon
7 and achieved recovery of dystrophin in skeletal muscle. To date, however, antisense chemical compounds used in DMD
animal models have not been directly applied to a DMD patient having the same type of exon deletion. We recently
identified a DMD patient with an exon 7 deletion and tried direct translation of the antisense PMO used in dog models to
the DMD patient’s cells.
Methodology/Principal Findings: We converted fibroblasts of CXMDJ and the DMD patient to myotubes by FACS-aided
MyoD transduction. Antisense PMOs targeting identical regions of dog and human dystrophin exons 6 and 8 were
designed. These antisense PMOs were mixed and administered as a cocktail to either dog or human cells in vitro. In the
CXMDJ and human DMD cells, we observed a similar efficacy of skipping of exons 6 and 8 and a similar extent of dystrophin
protein recovery. The accompanying skipping of exon 9, which did not alter the reading frame, was different between cells
of these two species.
Conclusion/Significance: Antisense PMOs, the effectiveness of which has been demonstrated in a dog model, achieved
multi-exon skipping of dystrophin gene on the FACS-aided MyoD-transduced fibroblasts from an exon 7-deleted DMD
patient, suggesting the feasibility of systemic multi-exon skipping in humans.
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Introduction
Antisense oligonucleotides (AON) have been reported to modu-
late splicing of pre-mRNA transcribed from mutated genes and
to restore a normal reading frame in several diseases. Duchenne
muscular dystrophy (DMD), a degenerative muscle disorder caused
mainly by nonsense or frame-shift mutations of the dystrophingene,
is one of the diseases that could be treated by AON-mediated exon
skipping. Previously reported studies were conducted in vitro,i n
animal models, and as patientintervention studies, and they showed
restorations of the reading frame in dystrophin mRNA and
recoveries of dystrophin protein expression [1,2,3]. Among the
several AON chemistries that have been introduced thus far, a
phosphorodiamidate morpholino oligomer(PMO) and 2’-O-methyl
phosphorothioate (2’OMe) oligomer are promising candidates
owing totheirstabilitiesandefficacies,and theyarenowundergoing
phase I-II clinical trials in the United Kingdom and the Nether-
lands, respectively [4,5]. The AON-mediated exon skipping is
already in a late early stage of clinical application; therefore, it is
rational to translate pre-clinical animal model knowledge into a
patient-based study.
We have previously reported that the systemic administration of
an antisense PMO for canine X-linked muscular dystrophy in
Japan (CXMDJ) achieved restoration of dystrophin and amelio-
ration of symptoms [6]. CXMDJ harbors a splice site mutation
within the splice acceptor site of intron 6 of the dystrophin gene.
The mutation disrupts the splicing of exon 7, and thus the
dystrophin mRNA lacks exon 7 [7]. In CXMDJ, multiple skipping
of exons 6 and 8 restores the reading frame, and the multi-exon
skipping approach is expected to expand the number of DMD
cases potentially treatable by exon skipping [8]. CXMDJ is an
ideal model of multi-exon skipping, and we hope to translate the
results to human patients. However, in the road to ongoing clinical
trials, in vitro assays on patient cells are indispensable.
To date, antisense sequences used for exon skipping in DMD
animal models have not been directly applied to a DMD patient
having the same type of exon deletion. We identified an exon 7-
deleted patient (referred to as DMD 8772) and tried direct
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12239translation of the antisense PMO design from a DMD dog model
to the DMD patient. We tried in vitro multi-exon skipping with the
same antisense PMO that was used in CXMDJ in the patient’s
cells before attempting delivery of the PMO into the patient.
Which cells should be used for in vitro dystrophin exon skipping
is controversial. Myoblasts are usually employed simply because
they express enough dystrophin as mRNA and protein, but
collecting them requires an invasive muscle biopsy. In cases where
myoblasts were not available, it had been reported that the
dystrophin mRNA was detected in lymphocytes and fibroblasts by
nested RT-PCR. Some studies actually demonstrated the success
of exon skipping in mRNA of lymphoblastoid cells and fibroblasts
[9,10], but the restoration of dystrophin protein could not be
analyzed in these cells because their transcripts were illegitimate
and too low to be translated into gene products [11]. As another
alternative, fibroblasts are converted to myotubes by MyoD
transduction [4,12,13]. Transduced cells express dystrophin
mRNA and protein, but achievement of sufficient protein
expression is challenging [14,15,16]. In this study, we addressed
this issue by introducing a retroviral vector co-expressing MyoD
and green fluorescent protein (GFP) and flow cytometry, and then
quantified the dystrophin expression of the cells to evaluate the
feasibility of exon skipping.
We first report multiple skipping of dystrophin exons 6 and 8 in
the DMD patient’s cells and translation of the unified antisense
PMO design from a DMD dog model to a human based on the
MyoD-transduction method utilizing flow cytometry.
Results
Mutation analysis of DMD 8772
DMD 8772, a 22-year-old man, manifested severe muscle
weakness, wheelchair dependency, and mild cardiac dysfunction.
No evidence of dystrophin protein had been observed on a previous
muscle biopsy, and the patient had been diagnosed with a frame-
shift deletion of dystrophin exon 7 by multiplex ligation-dependent
probe amplification (MLPA) analysis. The deletion of exon 7 leads
to a premature translation termination at exon 8. The deletion of
exon 9 is known as a common splice variant maintaining the
reading frame in dogs and humans [17,18] (Figure 1A). RT-PCR
analysis of dystrophin mRNA using the patient’s lymphocytes
showed an exon 7 deletion, and direct sequence analysis of the RT-
PCRproductsrevealeda conjunctionofexons6 and8(Figure1B).
To determinetheintronlength,weperformeda deletionbreakpoint
analysis. The genomic PCR roughly narrowed the breakpoint
window to 2.5 kb between introns 6 and 7, then primer walking
sequence analysis revealed the 50.4 kb deletion (Vega v35
chromosome X 32771568 to 32821979) [13] and the breakpoint
accompanying an insertion of 13 bases of unknown origin
(Figure 1C).
Myogenic conversion of fibroblasts by MyoD
transduction and selection of appropriate cell lineage for
exon skipping
We prepared lymphoblastoid cells, fibroblasts, and MyoD-
transduced fibroblasts from DMD 8772 and assessed the feasibility
of exon skipping in these cells. To establish MyoD-transduced
fibroblasts, primary fibroblasts were transfected by a retrovirus
encoding murine or human MyoD and GFP with the vesicular
stomatitis virus (VSV-G) envelope through standard procedures
(Figure 2A) [19,20]. To compare exon skipping between corres-
ponding cells of CXMDJ and DMD 8772, fibroblasts from both
were converted. In addition, normal dog and human fibroblasts
were also transduced for evaluation. After virus transfection, we
sorted GFP-positive cells by flow cytometry. The ratio of GFP-
positive to -negative cells was dependent on cell lineage, and affected
cells generally showed lower transfection efficiencies (Figure 2B).
The GFP-positive cells were isolated in serum-deprived medium for
myogenic differentiation and cultured for 10 to 16 days. We
confirmed that the cultured cells had the morphological features of
myotubes of multiple nuclei and longitudinal growth. Immunostain-
ing analysis showed nuclear localization of MyoD and expressions of
the muscle-specific proteins desmin, myosin heavy chain, and
dystrophin (Figure 2C). Using normal dog and human fibroblasts,
we performed time-course expression analyses of dystrophin mRNA
by qRT-PCR and dystrophin protein by Western blot. The results
showed a gradual increase in dystrophin expression. In dog cells,
dystrophin became detectable on the protein level seven days after
differentiation, whereas human cells required two weeks or more
(Figure2D).Wecompared the dystrophinmRNAexpression of the
lymphoblastoid cells, fibroblasts, and MyoD-transduced fibroblasts
from DMD 8772. The MyoD-transduced fibroblasts showed
remarkable expression compared with the other cells (Figure 2E).
We tried exon skipping in lymphoblastoid cells, fibroblasts and
MyoD-transduced fibroblasts, but only the MyoD-transduced
Figure 1. Mutation analysis of DMD 8772. (A) Splice-site mutation
of a splice acceptor site in intron 6 (asterisk) excludes exon 7 from dog
dystrophin mRNA. Frame-shift deletion of dystrophin exon 7 in DMD
8772 was diagnosed by MLPA analysis. Skipping of exon 9 is a frequent
splice variant. Both ends of the schematic box of the exon represent a
phase of the codon (see detail, Yokota et al. 2009). (B) RT-PCR and
sequence analysis of dystrophin mRNA using normal and DMD 8772
lymphocytes. Double bands due to a splicing variant of exon 9 were
observed. (C) Breakpoint analysis of DMD 8772 revealed a 50.4 kb
deletion from intron 6 to intron 7, and the insertion of 13 bases of
unknown origin.
doi:10.1371/journal.pone.0012239.g001
Dog PMO Treated DMD Cells
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fibroblasts often failed to producePCR products, and the skipped in-
frame products were undetectable even if PCR products were
generated (data not shown). Therefore, we used MyoD-
transduced fibroblasts in the subsequent assays.
Antisense PMO sequence design
In a previous systemic dog study, we used three antisense
sequences, Ex6A, Ex6B, and Ex8A, as three antisense PMO
cocktails [6]. Because there were two base mismatches between
dog and human Ex6B, hEx6B was newly designed on the identical
region of Ex6B, modifying the mismatches of the human sequence.
In the systemic study, we skipped exon 6 with a combination of
Ex6A and Ex6B, and thus we tried same strategy for exon 8. We
newly designed several antisense PMOs targeting exon 8 that were
positioned on the identical sequence in dog and human con-
sidering the predicted in silico splice-enhancer motifs (Figure 3A).
A preliminary assay of CXMDJ cells showed that three sequences,
Ex8G, Ex8I, and Ex8K, were effective. Therefore, the antisense
combination for exon 8 contained an extra antisense sequence
Figure 2. Myogenic conversion of fibroblasts and dystrophin expression. (A) Schematic diagram of the retroviral expression vector. (B)
Histograms showing GFP fluorescence intensity compared with cell numbers of normal human and DMD 8772 MyoD-GFP-transduced fibroblasts.
Both cells were analyzed five days after retroviral transfection. (C) Immunostaining of MyoD-transduced of dog and human fibroblasts after 10 and 15
days of myogenic differentiation, respectively. MyHC, myosin heavy chain. The nuclei were counter-stained with DAPI. Scale bar: 100 mm. (D) The time
course of dystrophin expression in dog and human MyoD-transduced fibroblasts by qRT-PCR and immunoblotting analysis. The mRNA levels were
normalized to GAPDH and expressed relative to the amount of the lowest one in each group. For immunoblotting, 5 mg of total protein was loaded
into each lane. Error bars indicate standard deviation. (E) Determination of dystrophin mRNA expression in each cell type from DMD 8772 by qRT-PCR.
MyoD-transduced fibroblasts were assayed 15 days after differentiation. Normalization and relative expression are the same as (D).
doi:10.1371/journal.pone.0012239.g002
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skipping efficacy of each combination was higher than that of
Ex8A alone, and those of Ex8G, Ex8I, and Ex8K were
comparable (Figure 3C).
Comparison of multiple skipping of exons 6 and 8
between CXMDJ and DMD 8772 cells
The multi-exon skipping of exons 6 and 8 employed three- and
four-antisense PMO cocktails. In the three-antisense PMO cocktail
for dogs, Ex6A, Ex6B, and Ex8A were included, and Ex6B was
replaced with hEx6B for the human. The four-antisense PMO
cocktail included one of Ex8G, Ex8I, or Ex8K in addition to the
three-antisense PMO cocktail (Figure 4A). When we transfected
the three- or four-antisense PMO cocktails into the MyoD-transduced
fibroblasts, we did not observe the skipped products (231 bp) of
exons 6-8 on RT-PCR analyses of CXMDJ but did observe the
skipped products (99 bp) of exons 6-9. A sequence analysis also
confirmed the concatenation of exons 5 and 10. In DMD 8772, we
observed skipped products (221 bp and 92 bp, respectively) of both
exons 6-8 and exons 6-9. Sequence analysis also showed that the
skipped products wereconcatenations of exons 5 to 9 and exons 5 to
10.The four-PMO cocktails produced more in-frame products than
the three-PMO cocktail, but we discerned no difference among the
four PMO cocktails. This tendency was also consistent between
CXMDJ and DMD 8772 (Figure 4B). Immunostaining analysis
showed partial recovery of dystrophin in the four-antisense PMO
Figure 3. Design of antisense PMO sequence targeting exons 6 and 8. (A) Exonic splicing enhancer motifs predicted in silico based on
human sequence (small coloured boxes) and positions of antisense PMOs (green and blue rectangular areas). The horizontal axis represents base
positions in each exon from 59 to 39, and the vertical axis represents relative predicted values of the motifs. PESE: putative exonic splicing enhancer.
ESE: exonic splicing enhancer. Base mismatches between dog and human (black bar) are indicated in the exon (grey box). RT-PCR of dystrophin
mRNA of MyoD-transduced CXMDJ fibroblasts treated with (B) a mixture of Ex6A and Ex6B and (C) only Ex8A or mixtures containing Ex8A.
doi:10.1371/journal.pone.0012239.g003
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(Figure 4C). Western blots of dystrophin showed products that
were slightly smaller than the full-length dystrophin. In RT-PCR of
DMD 8772, skipped mRNA of both exons 6-8 and 6-9 were
detected; however, distinguishing the truncated dystrophins trans-
lated from these mRNA variants was impossible. Similar to the RT-
PCR results, the dystrophin expression level was higher with a four-
PMO cocktail than with the three-PMO cocktail. Differences
between the four-PMO cocktails were also undetectable.
Discussion
In this study, we accomplished in vitro multi-exon skipping in a
DMD patient carrying the same deletion as CXMDJ by using the
identical antisense PMO. We also addressed the efficient MyoD
transduction of fibroblasts with FACS, and discuss the difference
of the spliced exon associated with it with the frequency of
alternative splicing.
FACS-aided MyoD transduction provided sufficient
dystrophin expression
We evaluated the appropriateness of lymphoblastoid cells,
fibroblasts, and MyoD-transduced fibroblasts as an alternative to
myoblasts for exon-skipping assays. Lymphoblastoid cells and
primary fibroblasts dystrophin mRNA required reamplification by
nested RT-PCR [9,10], and the results were not reproducible,
suggesting that low dystrophin expression may hamper reliable
quantitativeassessments. Only MyoD-transducedfibroblasts showed
reproducible results due to their stable dystrophin expression. We
employed flow cytometry for selection of MyoD-positive cells; it
seems to offer several advantages against conventional drug-
resistance selection. First, the transfection ratio in drug-resistance
selection remains unknown until a selective drug is added. In
contrast, with MyoD-transduced fibroblasts, we were able to
roughly determine the ratio by fluorescence microscopy and adjust
the culture scale to meet the size of the assay. Second, a low rate of
myotubes formation after drug-resistance selection has been
reported [21]. Our method actively selects MyoD-positive cells
and enables pure clusters of MyoD-positive cells to form myotubes
efficiently. MyoD transduction with GFP has been reported in
several studies [22,23] but not in dystrophin exon-skipping studies.
Wedemonstratedthat itisa suitableapproachfortheexon-skipping
assay here as well. Severalstudies have reported difficulties inducing
dystrophin in human cells with MyoD transduction [14,15,16]. In
our experience, the typical morphological features of myotubes,
multiple nuclei and longitudinal cell growth, do not necessarily
indicate sufficient dystrophin expression. Seeding MyoD-positive
cellsathigh density(.5.0610
4 cells/cm
2) and incubatingforlonger
periods (.2 weeks) were critical to induce sufficient dystrophin
expression. Detachment of differentiated myotubes from culture
wells was also problematic; supporting them with a coating matrix
seems to promise better results.
Direct translation of antisense PMO from dog to human
was feasible
We previously reported systemic multi-exon skipping in CXMDJ
with a 3-antisense PMO cocktail and amelioration of dystrophic
pathology [6]. The effectiveness of the 3-antisense PMO cocktail
was confirmed in MyoD-transduced fibroblasts derived from DMD
8772 as well. When the dog and human sequences were compared,
97% of dystrophin exon 6 and 95% of dystrophin exon 8 matched
on the sequence level. This similarity enabled use of the unified
antisense design methodology targeting the same sequence. We
demonstrated that the identical antisense PMO sequence designed
for dog and achieved multi-skipping of exons 6 and 8 in human
cells. The skipping efficacies of the PMOs were indistinguishable
between CXMDJ and DMD 8772; the superior efficacy of the four-
PMO cocktail against that of the three-PMO cocktail and the
equivalent efficacies of each four-PMO cocktail were comparable.
CXMDJ shows more similarity in the pathogenic phenotype to
human DMD than to mdx mice [24]. These findings imply that not
only the similarity in the sequence but also the similarity in the
pathogenic phenotype contributed to the comparable results.
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Figure 4. Multi exon skipping and recovery of dystrophin in
CXMDJ and DMD 8772-derived cells. (A) Schematic diagram of the
three- and four-antisense PMO cocktails. For DMD 8772, Ex6B was
replaced with hEx6B. In the four-antisense PMO cocktail, one additional
sequence (Ex8G, Ex8I, or Ex8K) was added to the three-antisense PMO
cocktail. (B) RT-PCR of dystrophin mRNA isolated from MyoD-
transduced fibroblasts after treatment with the three- and four-
antisense PMO cocktails. In-frame exon skipping products were 99 bp
in dog and 221 bp and 92 bp in human. (C) Representative immuno-
staining and immunoblotting analysis of MyoD-transduced fibroblasts
treated with antisense PMO cocktails. The nuclei were counterstained
with DAPI. Scale bar: 100 mm. Expected molecular weights of truncated
human dystrophin with exons 6–8 and exons 6–9 skipped are 18.3 kDa
and 23.1 kDa, respectively, smaller than the full-length dystrophin.
doi:10.1371/journal.pone.0012239.g004
Dog PMO Treated DMD Cells
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12239No study has yet compared the exon skipping due to identical
antisense PMOs between cells of different species carrying same
exon deletion in mRNA. Recent investigations have reported a
limitation in designing efficient antisenses to induce human
dystrophin skipping in a mice model assay [25]; however, we
confirmed the feasibility of direct translation of an antisense PMO
from a DMD dog model to a DMD patient, at least in vitro, for the
first time.
The four-antisense PMO cocktail, the addition of a fourth
antisense sequence to the three-antisense PMO cocktail, increased
the efficiency of skipping as previously reported [26,27]. The
effectiveness of the four-antisense PMO cocktails, however, must
be evaluated in vivo, and we are planning systemic treatment of
CXMDJ with them. Our results underscore the usefulness of
CXMDJ as a DMD model for translational research and advance
the prospect that systemic treatment of the DMD patient by multi-
exon skipping is possible.
Mode of exon 9 skipping might be affected by frequency
of alternative splicing
With the antisense PMO targeting exons 6 and 8, exon 9 was
always skipped in CXMDJ, although it was only partially skipped
in DMD 8772. Two possibilities were considered to explain the
difference: (1) the effects of the shortened introns 6 and 7 due to
the deletion around exon 7 in DMD 8772 (Figure 5), and (2) the
different frequencies of alternative splicing of exon 9. For the
former case, we tried exon 8 skipping using a combination of
Ex8A and Ex8G in normal and affected human MyoD-transduced
fibroblasts, and found that the skipping of exon 8 and exons 8/9
happened simultaneously (Figure S1). Therefore, it is unlikely
that the intron length affects the difference. In the latter case, the
untreated MyoD-transduced fibroblasts from CXMDJ clearly
showed one normal and one alternative transcript; on the other
hand, the untreated sample from DMD 8772 showed only a
normal transcript, suggesting that the frequency of alternative
splicing of exon 9 is an underlying factor in the difference. It was
reported that an antisense oligonucleotide targeting exon 8
facilitates the skipping of exon 9 as well as exon 8 by effecting
the concatenation of exons 8 and 9 in human and dog cells [28].
These findings were observed in myoblasts but not in MyoD-
tansduced fibroblasts [29,30,31]. As is well known, the mode of
alternative splicing differs among various tissues [32,33], and our
MyoD-transduced fibroblasts might have characteristics that are
incompatible with the alternative splicing of exon 9.
In summary, MyoD transduction of fibroblasts with the help of
FACS may be practical for exon skipping assays, and the direct
translation of an antisense PMO from a DMD dog model to a
DMD patient was feasible in vitro, suggesting that the animal
model-based antisense PMO for multiple skipping could be
effective for humans as well.
Materials and Methods
Ethics Statement
The patient samples were collected and used with the approval
of the Ethics Committee of the National Center of Neurology and
Psychiatry, approval ID: 20-4-6. Written informed consent was
obtained from the donor. The dog study was approved by the
Ethics Committee for the Treatment of Middle-sized Laboratory
Animals of the National Center of Neurology and Psychiatry,
approval ID: 20-05.
Cell culture
Dog primary myoblasts and fibroblasts were obtained from
muscle specimens of normal and affected neonatal dogs of the
CXMDJ colony using a standard pre-plating technique. Primary
fibroblasts of the DMD patient (DMD 8772) were obtained from
skin explants and peripheral blood lymphocytes using Lymphocyte
Separating Medium (PAN Biotech GmbH, Aidenbach, Germany).
Lymphoblastoid cell lines were established by transformation with
Epstein-Barr virus. The normal human fibroblast cell line TIG-
119 was obtained from the Health Science Research Resource
Bank (Osaka, Japan). Fibroblasts were cultured in 20% or 10%
growth medium containing DMEM/F-12 1:1 (Invitrogen, San
Diego, CA, USA), 20% or 10% fetal bovine serum, and 1%
penicillin/streptomycin. For differentiation to myotubes, FACS-
sorted MyoD-transduced fibroblasts were cultured in 2% differ-
entiation medium containing DMEM/F-12 1:1, 2% horse serum,
ITS Liquid Media Supplement (Sigma-Aldrich, St. Louis, MO,
USA), and 1% penicillin/streptomycin.
Genomic mutation analysis
The dystrophin exon 7-deletion of DMD 8772 had been
identified previously by MLPA. For breakpoint detection,
lymphocyte genomic DNA was used as a template. Seven pairs
of intron-spanning primers, positioned in the intron 6/7, were
designed to yield 150-600 bp PCR products. A failure of PCR
indicated deletions spanning the primer annealing sites. Four of
seven primer pairs showed no amplification, suggesting that the
deletion was more than 3.5 kb and less than 64.4 kb. Additionally,
two intron 6 sense-primers and eight intron 7 antisense-primers
were designed. Each primer pair was placed by flanking the
breakpoint and expected to yield PCR products within the range
of 4–64 kb. Primer sequences are available on request. PCR was
performed using Phusion Hot Start High-Fidelity DNA Polymer-
ase (Finnzymes, Keilaranta, Finland), and the cycling program was
set to yield 16 kb products with a program of 35 cycles of 98uC for
10 sec, 60uC for 30 sec, and 72uC for 450 sec. Failure of PCR
indicated products of more than 16 kb in size or the deletion of
annealing sites. The breakpoint region was thus narrowed down to
2.5 kb, then primer walk sequencing was performed (Operon
Biotechnologies, Tokyo, Japan).
Figure 5. Location of dystrophin exons 5 to 11 in the genome.
Distances from dystrophin exon 6 to exon 8 are indicated based on the
GenBank reference sequences of Canis familiaris chromosome X
genomic contig, whole genome shotgun sequence (NW_879562.1)
and Homo sapiens 211000035840903 genomic scaffold, whole genome
shotgun sequence (CH471074.1).
doi:10.1371/journal.pone.0012239.g005
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The coding sequences of mouse Myod1 (CCDS 21277.1) and
human MYOD1 (CCDS 7826.1) were derived from the Consensus
CDS database [34]. The sequences were synthesized and cloned
into a pUC57 vector (GenScript, Piscataway, NJ, USA). We
subcloned it into a pRetroX-IRES-ZsGreen1 expression vector
(Clontech, Mountain View, CA, USA). The expression vector, a
pVSV-G envelope vector, and a gap-pol expression vector were
co-transfected into a 293T packaging cell line using the standard
calcium phosphate method. After 48–72 h incubation, the viral
supernatant was collected and stored at 280uC. For retroviral
transduction, the fibroblasts were harvested at 70–80% confluence
in a T225 flask, and 2.5 ml thawed retroviral stock was added to
35 ml of growth medium. We added polybrene (Sigma-Aldrich) to
a final concentration of 8 mg/ml. After 48–72 h incubation at
32uC, the culture medium was replaced with fresh growth
medium, the cells were incubated at 37uC 1–3 d more, until the
GFP-positive cells exceeded approximately 60%. Cell sorting was
performed on a FACS VantageSE or FACSAria flow cytometry
system (BD Bioscience, Franklin Lakes, NJ, USA). The recovered
GFP-positive cells were seeded in Matrigel (BD Bioscience)-coated
well plates at density of 5610
4 cell/cm
2. After confirmation of cell
attachment, the culture medium was changed to 2% differentia-
tion medium. We cultured MyoD-transduced fibroblasts for 10 to
16 d to differentiate to myotubes.
Antisense PMO design and transfection to cultured cells
The antisense PMO sequences Ex6A, Ex6B, and Ex8A were
described in Yokota et al. [6]. In addition, extra sequences hEx6B,
Ex8G, Ex8I, and Ex8K were designed and synthesized (Gene
Tools, LLC, Philomath, OR, USA). We used the Human Splicing
Finder for in silico prediction of the splice-enhancer motifs [35].
All sequences are shown in Table S1. We transfected the
antisense PMOs into myotubes differentiated from MyoD-
transduced fibroblasts with a transfection agent, Endo-Porter
(Gene Tools). In the 2% differentiation medium, the final
concentration of the antisense PMO was 10 mM for a single
sequence, 20 mM for two sequences, and a total of 30 mM for three
or four sequences. A final concentration of Endo-Porter was
6 mM. After 48–72 h incubation with the PMO, the medium was
changed to a fresh culture medium free of PMOs. The cells were
recovered for analysis after 24–48 h in the PMO-deprived
medium to allow sufficient time to translate dystrophin protein.
Quantitative RT-PCR analysis
Total RNA was extracted from MyoD-transduced fibroblasts
obtained from normal subjects using Trizol (Invitrogen) at the time
points specified. Total RNA (100-200 ng) was employed for cDNA
synthesis using a QuantiTect Reverse Transcription Kit (Qiagen,
Hilden, Germany). Quantitative real-time PCR was performed
using ExTaq II SYBR (Takara, Kyoto, Japan) and a MyiQ Single-
Color Real-Time PCR detection system (Bio-Rad, Hercules, CA).
Primer sequences are shown in Table S2. Expression of
dystrophin mRNA was normalized to GAPDH mRNA, and the
time course of the increment was calculated by the delta-delta-Ct
method.
RT-PCR and sequence analysis
As well as quantitative RT-PCR analysis, total RNA extraction
and cDNA synthesis were performed. For myoblasts and MyoD-
transduced fibroblasts, 35 cycles of denaturing at 98uC for 10 sec,
annealing at 63uC for 30 sec, and extension at 72uC for 1 min
were performed with ExTaq DNA polymerase (Takara). For
fibroblasts and lymphoblasts, nested PCR was performed. Primer
sequences are shown in Table S3. PCR products were
electrophoresed on 1.2% SeaKem LE agarose gel (Lonza, Basel,
Switzerland). The bands of interests were excised using a Wizard
SV Gel and PCR Clean-Up system (Promega, Fitchburg, WI,
USA), then sequenced directly or cloned into a vector using a
TOPO-TA Cloning Kit (Invitrogen) with standard cloning
techniques. Sequencing was performed by Fasmac Corporation
(Kanagawa, Japan).
Immunostaining analysis
Cells were fixed in 3% paraformaldehyde, permeabilized in
10% Triton-X, then blocked by 10% goat serum in PBS for 1 h at
room temperature. The cells were incubated with the primary
antibody for 1 h at room temperature using anti-dystrophin (NCL-
Dys1, diluted 1:30, Novocastra, Newcastle upon Tyne, UK), anti-
myosin heavy chain (NCL-MHCf, diluted 1:30, Novocastra), anti-
MyoD (NCL-MyoD1, diluted 1:30, Novocastra), or anti-desmin
(NCL-DES-DERII, diluted 1:30, Novocastra). Incubation with the
secondary antibody was performed for 30 min at room temper-
ature using anti-rabbit or anti-mouse IgG (Alexa Fluor 546 highly
cross-adsorbed, diluted 1:300, Invitrogen). Antibodies were diluted
in Can Get Signal Immunostain A solution (Toyobo, Osaka,
Japan). To visualize nuclei and enhance fluorescence signals, cells
were mounted with Pro Long Gold Antifade reagent (Invitrogen).
Immunoblotting analysis
Protein was extracted from cultured cells using RIPA buffer
(Thermo Fisher Scientific, Rockford, IL, USA) containing
Complete Mini (Roche Applied Science, Indianapolis, IN, USA)
as a protease inhibitor. Protein concentrations were determined
using a BCA protein assay kit (Thermo Fisher Scientific) and
equalized. After being mixed with an equal volume of EzApply
sample buffer (ATTO Corporation, Tokyo, Japan), cell lysates
containing equal amounts of total protein were denatured at 95uC
for 5 min, electrophoresed in NuPAGE Novex Tris-Acetate Gel
3–8% (Invitrogen) at 150 V for 75 min, and transferred onto an
Immobilon-P membrane (Millipore Corp., Billerica, MA, USA).
Membranes were blocked for 1 h with 5% ECL Blocking agent
(GE Healthcare, Buckinghamshire, UK) and probed with anti-
dystrophin antibody (NCL-Dys1, diluted 1:50, Novocastra),
followed by incubation with peroxidase-conjugated goat-anti-
mouse IgG (Bio-Rad). An ECL Plus Western blotting system (GE
Healthcare) was used to detect protein bands.
Supporting Information
Figure S1 RT-PCR of dystrophin mRNA isolated from the
normal and affected human MyoD-transduced fibroblasts after the
single exon 8 skipping.
Found at: doi:10.1371/journal.pone.0012239.s001 (0.30 MB
PDF)
Table S1 Sequences of antisense PMO for dystrophin gene (for
dog and human if not specified).
Found at: doi:10.1371/journal.pone.0012239.s002 (0.07 MB
PDF)
Table S2 Sequences of qRT-PCR primers.
Found at: doi:10.1371/journal.pone.0012239.s003 (0.07 MB
PDF)
Table S3 Sequences of RT-PCR primers.
Found at: doi:10.1371/journal.pone.0012239.s004 (0.07 MB
PDF)
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